Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System
Wang et al.,
Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System,
medRxiv, doi:10.1101/2020.06.11.20128926 (Preprint)
Database analysis of 7,592 patients in NYC, showing adjusted HCQ mortality odds ratio OR 0.96,
p = 0.82, and HCQ+AZ OR 0.94,
p = 0.63
This study is excluded in the after exclusion results of meta
analysis:
confounding by indication is likely and adjustments do not consider COVID-19 severity at baseline.
risk of death, 5.8% lower, RR 0.94, p = 0.63, treatment 1,866, control 5,726, odds ratio converted to relative risk.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Wang et al., 10 Jun 2020, retrospective, database analysis, USA, preprint, 3 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128926; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US
Urban Healthcare System
Short title: Comorbidity and Sociodemographic determinants in COVID-19 mortality
An-Li Wang, PhD1,2; Xiaobo Zhong, DrPH4,5; Yasmin L Hurd, PhD1,2,3,6
1. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York,
USA
2. Addiction Institute of Mount Sinai, Icahn School of Medicine at Mount Sinai, New
York, USA
3. Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New
York, USA
4. Department of Population Health Science and Policy, Icahn School of Medicine
at Mount Sinai, New York, USA
5. Tisch cancer institute, Icahn School of Medicine at Mount Sinai, New York, USA
6. Behavioral Health System, Mount Sinai, New York, USA
Correspond to An-Li Wang, PhD
Department of Psychiatry
Addiction Institute of Mount Sinai
Icahn School of Medicine at Mount Sinai
1399 Park Ave Suit 320-B
New York, USA
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128926; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Email: an-li.wang@mssm.edu, anliwang@gmail.com
Tel: +1 212-585-4668
Conflict of Interest: All authors acknowledge no conflict of interest.
Funding: This study is supported by the institutional fund of the Icahn School of
Medicine at Mount Sinai.
Total word count: 2,805
2
medRxiv preprint doi: https://doi.org/10.1101/2020.06.11.20128926; this version posted June 12, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
ABSTRACT
Background: New York City is the US epicenter of the coronavirus disease 2019
(COVID-19) pandemic. Early international data indicated that comorbidity contributes
significantly to poor prognosis and fatality in patients infected with SARS-CoV-2. It is not
known to what degree medical comorbidity and sociodemographic determinants impact
COVID-19 mortality in the US.
Methods: Evaluation of de-identified electronic health records of 7,592 COVID-19
patients confirmed by SARS-CoV-2 lab tests in New York City. Medical comorbidites
and outcome of mortality, and other covariates, including clinical, sociodemographic,
and medication measures were assessed by bivariate and multivariate logistic
regression models.
Results: Of common comorbid conditions (hypertension, chronic kidney disease,
chronic obstructive pulmonary disease, asthma, obesity, diabetes, HIV, cancer), when
adjusted for covariates, chronic kidney disease remained significantly associated with
increased odds of mortality. Patients who had more than one comorbidities, former
smokers, treated with Azithromycin without Hydroxychloroquine, reside within..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit